These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36243666)

  • 61. Herpes Zoster Risk in Immunocompromised Adults in the United States: A Systematic Review.
    McKay SL; Guo A; Pergam SA; Dooling K
    Clin Infect Dis; 2020 Oct; 71(7):e125-e134. PubMed ID: 31677266
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review.
    Chiyaka ET; Nghiem VT; Zhang L; Deshpande A; Mullen PD; Le P
    Pharmacoeconomics; 2019 Feb; 37(2):169-200. PubMed ID: 30367401
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination.
    Poirrier JE; DeMartino JK; Nagar S; Carrico J; Hicks K; Meyers J; Stoddard J
    Hum Vaccin Immunother; 2022 Nov; 18(5):2040328. PubMed ID: 35363119
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions.
    Sullivan KM; Farraye FA; Winthrop KL; Willer DO; Vink P; Tavares-Da-Silva F
    Vaccine; 2023 Jan; 41(1):36-48. PubMed ID: 36460534
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis.
    Mbinta JF; Nguyen BP; Awuni PMA; Paynter J; Simpson CR
    Lancet Healthy Longev; 2022 Apr; 3(4):e263-e275. PubMed ID: 36098300
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence.
    Parikh R; Singer D; Chmielewski-Yee E; Dessart C
    Hum Vaccin Immunother; 2023 Dec; 19(3):2263979. PubMed ID: 37967254
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence.
    Udayachalerm S; Renouard MG; Anothaisintawee T; Thakkinstian A; Veettil SK; Chaiyakunapruk N
    J Med Econ; 2022; 25(1):26-37. PubMed ID: 34791974
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Summary of the NACI Update on Herpes Zoster Vaccines.
    Warrington R; Ismail S;
    Can Commun Dis Rep; 2018 Sep; 44(9):220-225. PubMed ID: 31015813
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States.
    Lu A; Sun Y; Porco TC; Arnold BF; Acharya NR
    Ophthalmology; 2021 Dec; 128(12):1699-1707. PubMed ID: 33892049
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Herpes Zoster Vaccines.
    Harbecke R; Cohen JI; Oxman MN
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S429-S442. PubMed ID: 34590136
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Vaccination against herpes zoster in developed countries: state of the evidence.
    Drolet M; Oxman MN; Levin MJ; Schmader KE; Johnson RW; Patrick D; Mansi JA; Brisson M
    Hum Vaccin Immunother; 2013 May; 9(5):1177-84. PubMed ID: 23324598
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recombinant Zoster Vaccine (Shingrix
    Syed YY
    Drugs Aging; 2018 Dec; 35(12):1031-1040. PubMed ID: 30370455
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Risk factors for herpes zoster: should people with asthma or COPD be vaccinated?
    Safonova E; Yawn BP; Welte T; Wang C
    Respir Res; 2023 Jan; 24(1):35. PubMed ID: 36709298
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost-Effectiveness of Recombinant Zoster Vaccine for Adults Aged ≥50 Years in China.
    Jiang M; Yao X; Peng J; Feng L; Ma Y; Shi X; Fang Y; Fang H
    Am J Prev Med; 2023 Nov; 65(5):818-826. PubMed ID: 37182556
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials.
    Oostvogels L; Heineman TC; Johnson RW; Levin MJ; McElhaney JE; Van den Steen P; Zahaf T; Dagnew AF; Chlibek R; Diez-Domingo J; Gorfinkel IS; Hervé C; Hwang SJ; Ikematsu H; Kalema G; Lal H; McNeil SA; Mrkvan T; Pauksens K; Smetana J; Watanabe D; Weckx LY; Cunningham AL
    Hum Vaccin Immunother; 2019; 15(12):2865-2872. PubMed ID: 31216205
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older.
    Shiragami M; Mizukami A; Kaise T; Curran D; Van Oorschot D; Bracke B; Watanabe D
    Dermatol Ther (Heidelb); 2019 Jun; 9(2):281-297. PubMed ID: 30929219
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview.
    Dagnew AF; Vink P; Drame M; Willer DO; Salaun B; Schuind AE
    Hum Vaccin Immunother; 2021 Nov; 17(11):4132-4143. PubMed ID: 34190658
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine.
    Pieters Z; Ogunjimi B; Beutels P; Bilcke J
    Pharmacoeconomics; 2022 Apr; 40(4):461-476. PubMed ID: 35094374
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49 year old patients.
    Racine É; Gilca V; Amini R; Tunis M; Ismail S; Sauvageau C
    Vaccine; 2020 Sep; 38(40):6205-6214. PubMed ID: 32788132
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Community and patient values for preventing herpes zoster.
    Lieu TA; Ortega-Sanchez I; Ray GT; Rusinak D; Yih WK; Choo PW; Shui I; Kleinman K; Harpaz R; Prosser LA
    Pharmacoeconomics; 2008; 26(3):235-49. PubMed ID: 18282017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.